Cargando…
Oligosaccharides as Potential Therapeutics against Atherosclerosis
Atherosclerosis is the major cause of cardiovascular-disease-related death worldwide, resulting from the subendothelial accumulation of lipoprotein-derived cholesterol, ultimately leading to chronic inflammation and the formation of clinically significant atherosclerotic plaques. Oligosaccharides ha...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386248/ https://www.ncbi.nlm.nih.gov/pubmed/37513323 http://dx.doi.org/10.3390/molecules28145452 |
_version_ | 1785081616796745728 |
---|---|
author | Dabravolski, Siarhei A. Sukhorukov, Vasily N. Melnichenko, Alexandra A. Khotina, Victoria A. Orekhov, Alexander N. |
author_facet | Dabravolski, Siarhei A. Sukhorukov, Vasily N. Melnichenko, Alexandra A. Khotina, Victoria A. Orekhov, Alexander N. |
author_sort | Dabravolski, Siarhei A. |
collection | PubMed |
description | Atherosclerosis is the major cause of cardiovascular-disease-related death worldwide, resulting from the subendothelial accumulation of lipoprotein-derived cholesterol, ultimately leading to chronic inflammation and the formation of clinically significant atherosclerotic plaques. Oligosaccharides have been widely used in biomedical research and therapy, including tissue engineering, wound healing, and drug delivery. Moreover, oligosaccharides have been consumed by humans for centuries, and are cheap, and available in large amounts. Given the constantly increasing number of obesity, diabetes, and hyperlipidaemia cases, there is an urgent need for novel therapeutics that can economically and effectively slow the progression of atherosclerosis. In this review, we address the current state of knowledge in oligosaccharides research, and provide an update of the recent in vitro and in vivo experiments that precede clinical studies. The application of oligosaccharides could help to eliminate the residual risk after the application of other cholesterol-lowering medicines, and provide new therapeutic opportunities to reduce the associated burden of premature deaths because of atherosclerosis. |
format | Online Article Text |
id | pubmed-10386248 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103862482023-07-30 Oligosaccharides as Potential Therapeutics against Atherosclerosis Dabravolski, Siarhei A. Sukhorukov, Vasily N. Melnichenko, Alexandra A. Khotina, Victoria A. Orekhov, Alexander N. Molecules Review Atherosclerosis is the major cause of cardiovascular-disease-related death worldwide, resulting from the subendothelial accumulation of lipoprotein-derived cholesterol, ultimately leading to chronic inflammation and the formation of clinically significant atherosclerotic plaques. Oligosaccharides have been widely used in biomedical research and therapy, including tissue engineering, wound healing, and drug delivery. Moreover, oligosaccharides have been consumed by humans for centuries, and are cheap, and available in large amounts. Given the constantly increasing number of obesity, diabetes, and hyperlipidaemia cases, there is an urgent need for novel therapeutics that can economically and effectively slow the progression of atherosclerosis. In this review, we address the current state of knowledge in oligosaccharides research, and provide an update of the recent in vitro and in vivo experiments that precede clinical studies. The application of oligosaccharides could help to eliminate the residual risk after the application of other cholesterol-lowering medicines, and provide new therapeutic opportunities to reduce the associated burden of premature deaths because of atherosclerosis. MDPI 2023-07-17 /pmc/articles/PMC10386248/ /pubmed/37513323 http://dx.doi.org/10.3390/molecules28145452 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Dabravolski, Siarhei A. Sukhorukov, Vasily N. Melnichenko, Alexandra A. Khotina, Victoria A. Orekhov, Alexander N. Oligosaccharides as Potential Therapeutics against Atherosclerosis |
title | Oligosaccharides as Potential Therapeutics against Atherosclerosis |
title_full | Oligosaccharides as Potential Therapeutics against Atherosclerosis |
title_fullStr | Oligosaccharides as Potential Therapeutics against Atherosclerosis |
title_full_unstemmed | Oligosaccharides as Potential Therapeutics against Atherosclerosis |
title_short | Oligosaccharides as Potential Therapeutics against Atherosclerosis |
title_sort | oligosaccharides as potential therapeutics against atherosclerosis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386248/ https://www.ncbi.nlm.nih.gov/pubmed/37513323 http://dx.doi.org/10.3390/molecules28145452 |
work_keys_str_mv | AT dabravolskisiarheia oligosaccharidesaspotentialtherapeuticsagainstatherosclerosis AT sukhorukovvasilyn oligosaccharidesaspotentialtherapeuticsagainstatherosclerosis AT melnichenkoalexandraa oligosaccharidesaspotentialtherapeuticsagainstatherosclerosis AT khotinavictoriaa oligosaccharidesaspotentialtherapeuticsagainstatherosclerosis AT orekhovalexandern oligosaccharidesaspotentialtherapeuticsagainstatherosclerosis |